Limits...
Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study.

Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G - Br. J. Cancer (2002)

Bottom Line: The encouraging results obtained in this phase I-II study prompted us to apply the same approach in an adjuvant setting, to evaluate (i) time to relapse and (ii) overall survival.In the treated glioblastoma patients, median disease-free interval was 28 months (range=9-59); median survival was 33.5 months and one patient is still without evidence of disease.All 12 control glioblastoma patients died after a median survival from diagnosis of 8 months.

View Article: PubMed Central - PubMed

Affiliation: Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, I-20141, Milano, Italy.

Show MeSH

Related in: MedlinePlus

MR study of a female patient (47 years old; No. 16) who had surgery for glioblastoma in April 1996: set of images starting from the baseline evaluation to the last control (September 1999): no evidence of relapse. The patient is scheduled for a new MR in summer 2001.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375191&req=5

fig2: MR study of a female patient (47 years old; No. 16) who had surgery for glioblastoma in April 1996: set of images starting from the baseline evaluation to the last control (September 1999): no evidence of relapse. The patient is scheduled for a new MR in summer 2001.

Mentions: Figure 2Figure 2


Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study.

Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G - Br. J. Cancer (2002)

MR study of a female patient (47 years old; No. 16) who had surgery for glioblastoma in April 1996: set of images starting from the baseline evaluation to the last control (September 1999): no evidence of relapse. The patient is scheduled for a new MR in summer 2001.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375191&req=5

fig2: MR study of a female patient (47 years old; No. 16) who had surgery for glioblastoma in April 1996: set of images starting from the baseline evaluation to the last control (September 1999): no evidence of relapse. The patient is scheduled for a new MR in summer 2001.
Mentions: Figure 2Figure 2

Bottom Line: The encouraging results obtained in this phase I-II study prompted us to apply the same approach in an adjuvant setting, to evaluate (i) time to relapse and (ii) overall survival.In the treated glioblastoma patients, median disease-free interval was 28 months (range=9-59); median survival was 33.5 months and one patient is still without evidence of disease.All 12 control glioblastoma patients died after a median survival from diagnosis of 8 months.

View Article: PubMed Central - PubMed

Affiliation: Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, I-20141, Milano, Italy.

Show MeSH
Related in: MedlinePlus